Jasper Therapeutics starts offer to buy outstanding warrants

Jasper Therapeutics Inc. (JSPR) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on October 07, 2026. On October 7, 2026, Jasper Therapeutics, Inc. (the "Company") issued a press release announcing that it has commenced an offer to each holder of its outstanding warrants to purchase shares of its common stock, par value $0.0001 per share (the "Common Stock"), that were issued in the Company's underwritten public offering on September 18, 2025 (the "Warrants"). Under the offer, each holder may receive $0.324 in cash, without interest, for each outstanding Warrant the holder tenders (the "Offer"). Each Warrant entitles its holder to purchase one share of Common Stock at an exercise price of $2.92, subject to adjustment. As of October 6, 2026, 12,345,707 Warrants were outstanding. The Offer is made only on the terms and conditions set out in an Offer to Purchase, dated October 7, 2026, and other related offering materials that are being distributed to holders of the Warrants. The Offer will be open until one minute after 11:59 p.m., Eastern Time, on November 6, 2026, or any later date to which the Company may extend it. A copy of the press release is filed as Exhibit 99.1 to this report and is incorporated by reference into this Item 8.01. The full text of this SEC filing can be retrieved at: Any exhibits and associated documents for this SEC filing can be retrieved at: Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares. (END) Dow Jones Newswires October 07, 2026 08:06 ET (12:06 GMT) Copyright (c) 2026 Dow Jones & Company, Inc. The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.